Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
anti-KRAS G12D mTCR PBL
i
Other names:
anti-KRAS G12D mTCR PBL
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Gilead, National Cancer Institute - Bethesda
Drug class:
KRAS inhibitor, T lymphocyte replacement
Related drugs:
‹
MRTX1257 (4)
AZD4785 (1)
QTX3034 (1)
ATG-012 (0)
ELI-002 7P (0)
KRAS peptide vaccine (0)
SLATE-KRAS (0)
mRNA-5671 (0)
siG12D LODER (0)
lifileucel (1)
ATL 001 (0)
BNT221 (0)
C-TCR055 (0)
CYAD-01 (0)
CoTIL-01 (0)
H3.3K27M TCR T cell therapy (0)
IOV-2001 (0)
NeoTCR-P1 (0)
OBX-115 (0)
RAPA-201 (0)
allodepleted T-cell immunotherapeutics (0)
ThisCART22 (0)
UTIL-01 (0)
marrow infiltrating lymphocytes (0)
MT-401 (0)
MRTX1257 (4)
AZD4785 (1)
QTX3034 (1)
ATG-012 (0)
ELI-002 7P (0)
KRAS peptide vaccine (0)
SLATE-KRAS (0)
mRNA-5671 (0)
siG12D LODER (0)
lifileucel (1)
ATL 001 (0)
BNT221 (0)
C-TCR055 (0)
CYAD-01 (0)
CoTIL-01 (0)
H3.3K27M TCR T cell therapy (0)
IOV-2001 (0)
NeoTCR-P1 (0)
OBX-115 (0)
RAPA-201 (0)
allodepleted T-cell immunotherapeutics (0)
ThisCART22 (0)
UTIL-01 (0)
marrow infiltrating lymphocytes (0)
MT-401 (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login